# Mind Technology, Inc: financial statements, quarterly

MIND · Nasdaq · CIK 926423 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/mind.md) · [Financials](/companies/mind/financials.md) · [Filings](/companies/mind/filings.md) · [Insiders](/companies/mind/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mind/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.0](/filings/0001437749-24-037356.md) | [13.4 d](/filings/0001437749-25-013105.md) | [9.7](/filings/0001437749-25-020082.md) | [10.0](/filings/0001437749-25-028765.md) | [12.1](/filings/0001437749-25-037555.md) | [15.0 d](/filings/0001437749-26-012831.md) | [7.9](/filings/0001437749-26-020298.md) | [13.6](/filings/0001437749-26-029986.md) | [9.7](/filings/0001437749-25-037555.md) | [9.8 d](/filings/0001437749-26-012831.md) | [9.7](/filings/0001437749-26-020298.md) | [5.6](/filings/0001437749-26-029986.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [2.3](/filings/0001437749-24-037356.md) | [6.2 d](/filings/0001437749-25-013105.md) | [4.2](/filings/0001437749-25-020082.md) | [4.8](/filings/0001437749-25-028765.md) | [5.4](/filings/0001437749-25-037555.md) | [6.6 d](/filings/0001437749-26-012831.md) | [3.3](/filings/0001437749-26-020298.md) | [6.8](/filings/0001437749-26-029986.md) | [4.5](/filings/0001437749-25-037555.md) | [4.0 d](/filings/0001437749-26-012831.md) | [4.1](/filings/0001437749-26-020298.md) | [2.1](/filings/0001437749-26-029986.md) |
| Research and development | $m | [0.5](/filings/0001437749-24-037356.md) | [0.7 d](/filings/0001437749-25-013105.md) | [0.5](/filings/0001437749-25-020082.md) | [0.3](/filings/0001437749-25-028765.md) | [0.6](/filings/0001437749-25-037555.md) | [0.6 d](/filings/0001437749-26-012831.md) | [0.4](/filings/0001437749-26-020298.md) | [0.3](/filings/0001437749-26-029986.md) | [0.5](/filings/0001437749-25-037555.md) | [0.4 d](/filings/0001437749-26-012831.md) | [0.3](/filings/0001437749-26-020298.md) | [0.4](/filings/0001437749-26-029986.md) |
| Selling, general and administrative | $m | [2.9](/filings/0001437749-24-037356.md) | [3.0 d](/filings/0001437749-25-013105.md) | [2.8](/filings/0001437749-25-020082.md) | [2.8](/filings/0001437749-25-028765.md) | [2.8](/filings/0001437749-25-037555.md) | [3.0 d](/filings/0001437749-26-012831.md) | [3.4](/filings/0001437749-26-020298.md) | [3.6](/filings/0001437749-26-029986.md) | [3.0](/filings/0001437749-25-037555.md) | [3.3 d](/filings/0001437749-26-012831.md) | [3.5](/filings/0001437749-26-020298.md) | [3.3](/filings/0001437749-26-029986.md) |
| Operating income | $m | [(1.5)](/filings/0001437749-24-037356.md) | [2.3 d](/filings/0001437749-25-013105.md) | [0.7](/filings/0001437749-25-020082.md) | [1.4](/filings/0001437749-25-028765.md) | [1.9](/filings/0001437749-25-037555.md) | [2.8 d](/filings/0001437749-26-012831.md) | [(0.7)](/filings/0001437749-26-020298.md) | [2.7](/filings/0001437749-26-029986.md) | [0.8](/filings/0001437749-25-037555.md) | [0.1 d](/filings/0001437749-26-012831.md) | [0.0](/filings/0001437749-26-020298.md) | [(1.8)](/filings/0001437749-26-029986.md) |
| Interest expense | $m | [0.2](/filings/0001437749-23-034443.md) | not reported | [0.0](/filings/0001437749-24-019949.md) | [0.0](/filings/0001437749-24-029059.md) | [0.0](/filings/0001437749-24-037356.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0001437749-24-037356.md) | [0.7 d](/filings/0001437749-25-013105.md) | [0.2](/filings/0001437749-25-020082.md) | [0.7](/filings/0001437749-25-028765.md) | [0.4](/filings/0001437749-25-037555.md) | [0.7 d](/filings/0001437749-26-012831.md) | [0.3](/filings/0001437749-26-020298.md) | [0.7](/filings/0001437749-26-029986.md) | [0.7](/filings/0001437749-25-037555.md) | [0.5 d](/filings/0001437749-26-012831.md) | [0.5](/filings/0001437749-26-020298.md) | [0.0](/filings/0001437749-26-029986.md) |
| Net income | $m | [0.6](/filings/0001437749-24-037356.md) | [1.4 d](/filings/0001437749-25-013105.md) | [1.0](/filings/0001437749-25-037555.md) | [0.8](/filings/0001437749-25-037555.md) | [1.3](/filings/0001437749-25-037555.md) | [2.0 d](/filings/0001437749-26-012831.md) | [(1.0)](/filings/0001437749-26-029986.md) | [1.9](/filings/0001437749-26-029986.md) | [0.1](/filings/0001437749-25-037555.md) | [(0.3) d](/filings/0001437749-26-012831.md) | [(0.4)](/filings/0001437749-26-029986.md) | [(1.7)](/filings/0001437749-26-029986.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.27)](/filings/0001437749-24-037356.md) | not reported | [0.00](/filings/0001437749-25-020082.md) | [(0.11)](/filings/0001437749-25-028765.md) | [2.87](/filings/0001437749-25-037555.md) | not reported | [(120.00)](/filings/0001437749-26-020298.md) | [0.24](/filings/0001437749-26-029986.md) | [0.01](/filings/0001437749-25-037555.md) | not reported | [(50.00)](/filings/0001437749-26-020298.md) | [(0.19)](/filings/0001437749-26-029986.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.6](/filings/0001437749-23-034443.md) | [5.3](/filings/0001437749-25-013105.md) | [0.9](/filings/0001437749-24-019949.md) | [1.9](/filings/0001437749-24-029059.md) | [3.5](/filings/0001437749-24-037356.md) | [5.3](/filings/0001437749-26-012831.md) | [9.2](/filings/0001437749-25-020082.md) | [7.8](/filings/0001437749-25-028765.md) | [19.4](/filings/0001437749-25-037555.md) | [19.1](/filings/0001437749-26-029986.md) | [17.7](/filings/0001437749-26-020298.md) | [15.8](/filings/0001437749-26-029986.md) |
| Current assets | $m | [24.4](/filings/0001437749-23-034443.md) | [28.3](/filings/0001437749-25-013105.md) | [29.5](/filings/0001437749-24-019949.md) | [32.6](/filings/0001437749-24-029059.md) | [31.3](/filings/0001437749-24-037356.md) | [32.1](/filings/0001437749-26-012831.md) | [31.7](/filings/0001437749-25-020082.md) | [31.7](/filings/0001437749-25-028765.md) | [42.8](/filings/0001437749-25-037555.md) | [44.9](/filings/0001437749-26-029986.md) | [46.7](/filings/0001437749-26-020298.md) | [42.9](/filings/0001437749-26-029986.md) |
| Total assets | $m | [29.8](/filings/0001437749-23-034443.md) | [33.5](/filings/0001437749-25-013105.md) | [34.9](/filings/0001437749-25-020082.md) | [37.8](/filings/0001437749-25-028765.md) | [36.1](/filings/0001437749-25-037555.md) | [36.7](/filings/0001437749-26-012831.md) | [36.2](/filings/0001437749-26-020298.md) | [35.8](/filings/0001437749-26-029986.md) | [47.3](/filings/0001437749-25-037555.md) | [49.3](/filings/0001437749-26-029986.md) | [50.8](/filings/0001437749-26-020298.md) | [46.7](/filings/0001437749-26-029986.md) |
| Current liabilities | $m | [7.9](/filings/0001437749-23-034443.md) | [10.3](/filings/0001437749-25-013105.md) | [10.2](/filings/0001437749-24-019949.md) | [12.4](/filings/0001437749-24-029059.md) | [10.0](/filings/0001437749-24-037356.md) | [8.6](/filings/0001437749-26-012831.md) | [8.9](/filings/0001437749-25-020082.md) | [6.6](/filings/0001437749-25-028765.md) | [6.8](/filings/0001437749-25-037555.md) | [7.4](/filings/0001437749-26-029986.md) | [9.0](/filings/0001437749-26-020298.md) | [6.2](/filings/0001437749-26-029986.md) |
| Total liabilities | $m | [8.6](/filings/0001437749-23-034443.md) | [10.9](/filings/0001437749-25-013105.md) | [11.2](/filings/0001437749-24-019949.md) | [13.3](/filings/0001437749-24-029059.md) | [10.9](/filings/0001437749-24-037356.md) | [9.4](/filings/0001437749-26-012831.md) | [9.6](/filings/0001437749-25-020082.md) | [7.0](/filings/0001437749-25-028765.md) | [7.4](/filings/0001437749-25-037555.md) | [7.8](/filings/0001437749-26-029986.md) | [9.2](/filings/0001437749-26-020298.md) | [6.4](/filings/0001437749-26-029986.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [21.2](/filings/0001437749-24-037356.md) | [22.6](/filings/0001437749-26-012831.md) | [23.6](/filings/0001437749-25-037555.md) | [24.5](/filings/0001437749-25-037555.md) | [25.2](/filings/0001437749-25-037555.md) | [27.3](/filings/0001437749-26-029986.md) | [26.6](/filings/0001437749-26-029986.md) | [28.8](/filings/0001437749-26-029986.md) | [39.9](/filings/0001437749-25-037555.md) | [41.4](/filings/0001437749-26-029986.md) | [41.5](/filings/0001437749-26-029986.md) | [40.3](/filings/0001437749-26-029986.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,147) d](/filings/0001437749-24-037356.md) | [657 d](/filings/0001437749-25-013105.md) | [(4,753)](/filings/0001437749-25-020082.md) | [1,058 d](/filings/0001437749-25-028765.md) | [2,288 d](/filings/0001437749-25-037555.md) | [2,058 d](/filings/0001437749-26-012831.md) | [4,068](/filings/0001437749-26-020298.md) | [(1,159) d](/filings/0001437749-26-029986.md) | [894 d](/filings/0001437749-25-037555.md) | [(1,217) d](/filings/0001437749-26-012831.md) | [(1,346)](/filings/0001437749-26-020298.md) | [(1,790) d](/filings/0001437749-26-029986.md) |
| Capital expenditure | $k | [97.0 d](/filings/0001437749-24-037356.md) | [91.0 d](/filings/0001437749-25-013105.md) | [66.0](/filings/0001437749-25-020082.md) | [80.0 d](/filings/0001437749-25-028765.md) | [67.0 d](/filings/0001437749-25-037555.md) | [224 d](/filings/0001437749-26-012831.md) | [237](/filings/0001437749-26-020298.md) | [182 d](/filings/0001437749-26-029986.md) | [93.0 d](/filings/0001437749-25-037555.md) | [151 d](/filings/0001437749-26-012831.md) | [48.0](/filings/0001437749-26-020298.md) | [108 d](/filings/0001437749-26-029986.md) |
| Share repurchases | $k | [0.0 d](/filings/0001437749-23-034443.md) | [0.0 d](/filings/0001437749-24-013973.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2021 (2020-04-30) | Q2 FY2021 (2020-07-31) | Q3 FY2021 (2020-10-31) | Q1 FY2022 (2021-04-30) | Q2 FY2022 (2021-07-31) | Q3 FY2022 (2021-10-31) | Q1 FY2023 (2022-04-30) | Q2 FY2023 (2022-07-31) | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.2](/filings/0000926423-21-000027.md) | [12.2](/filings/0001628280-21-018340.md) | [12.3](/filings/0001437749-21-028312.md) | [13.8](/filings/0001437749-22-014677.md) | [13.8](/filings/0001437749-22-022313.md) | [13.8](/filings/0001437749-22-029082.md) | [13.8](/filings/0001437749-23-017412.md) | [13.8](/filings/0001437749-23-025903.md) | [1.4](/filings/0001437749-23-034443.md) | [13.8](/filings/0001437749-23-017412.md) | [13.8](/filings/0001437749-23-025903.md) | [1.4](/filings/0001437749-23-034443.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,089,055 at 2026-09-08, from the cover of the [10-Q filed 2026-09-09](/filings/0001437749-26-029986.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.